Data from Pharmawand - Curated by EPG Health - Date added 11 January 2019

In draft guidelines, the National Institute for Health and Care Excellence (NICE) has announced that it has decided that Aimovig (erenumab), from Novartis, cannot be funded by the NHS as preventative treatment for migraine. Aimovig was approved for use in Europe last year as the first treatment specifically designed to prevent migraine.

The EU approval is based on the phase IIIb LIBERTY trial, which assessed Aimovig in episodic migraine patients who had previously tried two to four therapies without success, showing that patients taking the drug had almost three-fold higher odds of having migraine days cut by half or more versus placebo. More than twice as many patients taking Aimovig achieved this reduction.

However, NICE argued that the evidence from the LIBERTY trial doesn’t fully reflect patients seen in clinical practice in the NHS and nor does it include all the relevant comparators and outcomes. The result of this is that cost-effectiveness estimates for the drug are higher than those normally considered acceptable.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Load more

Related Content